Literature DB >> 1373123

Acute optic neuritis associated with immunization with the CNS myelin proteolipid protein.

N T Potter1, P E Bigazzi.   

Abstract

Optic nerve tissue for SJL/J mice immunized with the central nervous system (CNS) myelin-specific proteolipid protein (PLP) was examined for histopathologic evidence of optic neuritis. Optic nerves isolated 17 d after immunization with PLP revealed an interstitial and submeningeal inflammatory infiltrate consisting of neutrophils and monocytes. In all cases, histologic evidence of optic nerve involvement correlated serologically with the presence of circulating anti-PLP antibodies. Control animals had no histopathologic evidence of disease or anti-PLP antibody. In many respects, the observed histopathologic profile of PLP-induced optic neuritis is similar to that associated with human inflammatory demyelinating diseases such as multiple sclerosis (MS). Because optic neuritis frequently is associated with some of the earliest clinical symptoms of MS, the acute nature of optic nerve involvement in this animal model suggests that immune recognition of the myelin PLP may play a significant role in the pathophysiology of optic nerve damage associated with sensitization to CNS-specific antigens.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1373123

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  12 in total

1.  Lipoic acid decreases inflammation and confers neuroprotection in experimental autoimmune optic neuritis.

Authors:  Priya Chaudhary; Gail Marracci; Xiaolin Yu; Danielle Galipeau; Brooke Morris; Dennis Bourdette
Journal:  J Neuroimmunol       Date:  2011-01-07       Impact factor: 3.478

2.  Oral resveratrol reduces neuronal damage in a model of multiple sclerosis.

Authors:  Kenneth S Shindler; Elvira Ventura; Mahasweta Dutt; Peter Elliott; Denise C Fitzgerald; Abdolmohamad Rostami
Journal:  J Neuroophthalmol       Date:  2010-12       Impact factor: 3.042

3.  Optic Neuritis: A Model for the Immuno-pathogenesis of Central Nervous System Inflammatory Demyelinating Diseases.

Authors:  Gregory F Wu; Chelsea R Parker Harp; Kenneth S Shindler
Journal:  Curr Immunol Rev       Date:  2015

4.  Analysis of the pathogenesis of experimental autoimmune optic neuritis.

Authors:  Takeshi Kezuka; Yoshihiko Usui; Hiroshi Goto
Journal:  J Biomed Biotechnol       Date:  2010-10-25

5.  Timing of corticosteroid therapy is critical to prevent retinal ganglion cell loss in experimental optic neuritis.

Authors:  Mahasweta Dutt; Philomela Tabuena; Elvira Ventura; Abdolmohamad Rostami; Kenneth S Shindler
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-11-05       Impact factor: 4.799

6.  Calpain inhibitor attenuated optic nerve damage in acute optic neuritis in rats.

Authors:  Arabinda Das; M Kelly Guyton; Amena Smith; Gerald Wallace; Misty L McDowell; Denise D Matzelle; Swapan K Ray; Naren L Banik
Journal:  J Neurochem       Date:  2012-11-22       Impact factor: 5.372

7.  Bilateral optic neuritis with branch retinal artery occlusion associated with vaccination.

Authors:  E J van de Geijn; R Tukkie; L A van Philips; H Punt
Journal:  Doc Ophthalmol       Date:  1994       Impact factor: 2.379

8.  Inflammatory demyelination induces axonal injury and retinal ganglion cell apoptosis in experimental optic neuritis.

Authors:  Kenneth S Shindler; Elvira Ventura; Mahasweta Dutt; Abdolmohamad Rostami
Journal:  Exp Eye Res       Date:  2008-06-03       Impact factor: 3.467

9.  In vivo detection of experimental optic neuritis by pupillometry.

Authors:  Kenneth S Shindler; Karen Revere; Mahasweta Dutt; Gui-Shuang Ying; Daniel C Chung
Journal:  Exp Eye Res       Date:  2012-04-24       Impact factor: 3.467

10.  Transgenic inhibition of astroglial NF-κB protects from optic nerve damage and retinal ganglion cell loss in experimental optic neuritis.

Authors:  Roberta Brambilla; Galina Dvoriantchikova; David Barakat; Dmitry Ivanov; John R Bethea; Valery I Shestopalov
Journal:  J Neuroinflammation       Date:  2012-09-10       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.